Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer

Friday, December 23, 2022 1 min read

Key Takeaway: Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer

Full Press Release Details

Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer.